Nicholas Investment Partners’s Viking Therapeutics VKTX Stock Holding History

Nicholas Investment Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-80,010	Closed	-$6.56M	–	238
2024 Q1	$6.56M	Buy	+80,010	New	+$3.56M	0.67%	48
2023 Q3	–	Sell	-68,905	Closed	-$1.12M	–	207
2023 Q2	$1.12M	Sell	68,905 -438,165	-86%	-$9.18M	0.08%	160
2023 Q1	$8.44M	Buy	+507,070	New	+$5.24M	0.64%	43
2019 Q3	–	Sell	-483,951	Closed	-$4.02M	–	223
2019 Q2	$4.02M	Sell	483,951 -10,779	-2%	-$92.1K	0.37%	99
2019 Q1	$4.92M	Sell	494,730 -3,232	-0.6%	-$27.1K	0.44%	71
2018 Q4	$3.81M	Sell	497,962 -82,066	-14%	-$981K	0.41%	88
2018 Q3	$10.1M	Buy	580,028 +63,237	+12%	+$753K	0.81%	25
2018 Q2	$4.9M	Buy	+516,791	New	+$3.44M	0.34%	88

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Nicholas Investment Partners's VKTX Position: Q2 2024 in Review

Nicholas Investment Partners sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 80,010 shares — an estimated $6.56M sold.

Nicholas Investment Partners first reported a position in VKTX in Q2 2018 and held it in 8 quarters. The position peaked at $10.1M in Q3 2018. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Nicholas Investment Partners reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
Nicholas Investment Partners sold 80,010 Viking Therapeutics shares in Q2 2024, an estimated $6.56M.
Nicholas Investment Partners first reported a position in Viking Therapeutics in Q2 2018 and held it in 8 quarters.
Nicholas Investment Partners's Viking Therapeutics position peaked at $10.1M in Q3 2018.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Nicholas Investment Partners's 13F filing for Q2 2024, filed 8 Aug 2024.